99314-44-0

Usage

Uses

Used in Dental Materials Industry:
3-METHYL-3-(TOLUENESULFONYLOXYMETHYL)OXETANE is used as a monomer or crosslinking agent for the production of dental materials and adhesives. It contributes to the improvement of the mechanical properties and overall performance of these materials, providing excellent adhesion and resistance to moisture.
Used in Polymer and Resin Production:
3-METHYL-3-(TOLUENESULFONYLOXYMETHYL)OXETANE is used as a monomer or crosslinking agent in the production of various polymers and resins. Its incorporation into polymer systems enhances their mechanical properties, making it a valuable component in the development of advanced materials for a wide range of industrial and medical applications.

Upstream product

• 3143-02-0 3-hydroxymethyl-3-methyloxethane 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 141100-23-4 bis-(3-methyloxetan-3-ylmethyl) ether 
• 84051-81-0 3-methyl-3-(nitroxymethyl)oxetane 
• 114644-08-5 Dimethyl-(3-methyl-oxetan-3-ylmethyl)-amine 
• 198572-36-0 1-(3-Methyl-oxetan-3-ylmethyl)-pyrrolidine-2,5-dione 
• 198572-37-1 1-(3-Methyl-oxetan-3-ylmethyl)-piperidine-2,6-dione 
• 206191-47-1 (2S,3R)-2-tert-Butoxycarbonylamino-3-hydroxy-butyric acid 3-methyl-oxetan-3-ylmethyl ester 
• 206191-42-6 (S)-(3-methyloxetan-3-yl)methyl 2-(((benzyloxy)carbonyl)-amino)-3-hydroxypropanoate 
• 206191-43-7 (S)-2-tert-Butoxycarbonylamino-3-hydroxy-propionic acid 3-methyl-oxetan-3-ylmethyl ester 
• 78385-26-9 3-bromomethyl-3-methyloxetane 
• 402578-38-5 (S)-3-Hydroxy-2-(2-nitro-benzenesulfonylamino)-propionic acid 3-methyl-oxetan-3-ylmethyl ester 
• 112823-30-0 3-(iodomethyl)-3-methyl-oxetane 
• 497870-37-8 ethyl 3-(3-methyloxetan-3-yl)propionate 
• 497870-42-5 2-(3-methyloxetan-3-ylmethoxy)-1-phenylethanone 
• 497870-36-7 diethyl 2-(3-methyloxetan-3-ylmethyl)malonate 

Relevant academic research and scientific papers

Synthesis and characterization of [60]fullerene-poly(3-azidomethyl-3-methyl oxetane) and its thermal decomposition

A new functionalized fullerene derivative, [60]fullerene-poly(3-azidomethyl-3-methyl oxetane) (C60-PAMMO), was synthesized for the first time using a modified Bingel reaction with [60]fullerene (C60) and bromomalonic acid poly(3-azidomethyl-3-methyl oxetane) ester (BM-PAMMO). The product was characterized by Fourier transform infrared (FTIR), ultraviolet-visible (UV-vis), and nuclear magnetic resonance (NMR) spectroscopy analyses. The results confirmed the successful preparation of C60-PAMMO. Moreover, the thermal decomposition of C60-PAMMO was analyzed by differential scanning calorimetry (DSC), thermogravimetric analysis coupled with infrared spectroscopy (TG-IR), and in situ FTIR spectroscopy. The decomposition of C60-PAMMO showed a three-step thermal process. The first step at approximately 150 °C was related to the cycloaddition of the azido groups (-N3) with [60]fullerene. The second step was ascribed to the decomposition of the remaining PAMMO main chain at approximately 320 °C. The final step was attributed to the burning decomposition of amorphous carbon, the main chain, N-heterocyclic components and the carbon cage around 510 °C.

SPOCC: A resin for solid-phase organic chemistry and enzymatic reactions on solid phase

SPOCC resin 1, a novel, highly permeable, polar support for chemical and enzymatic solid-phase methods, is presented. The synthesis of SPOCC resin is based on the cross-linking of long-chain poly(ethylene glycol) (PEG) terminally substituted with oxetane by cationic ring-opening polymerization, affording a polymer containing only primary ether and alcohol C-O bonds. The polymer was prepared using Et2O-BF3 as initiator either via bulk polymerization in solution or via suspension polymerization in silicon oil, the latter yielding a beaded resin. The polymerization reaction was investigated with respect to the effects of PEG chain length, the fraction of bisoxetanylated PEG, initiator amount, and temperature in order to vary the swelling, loading, and mechanical stability of the resin. Furthermore, the resin was derivatized with various functional groups and subsequently applied to peptide synthesis and organic reactions in both organic solvents and water. An N-terminal peptide aldehyde was generated on the solid phase and employed to synthesize peptide isosteres by nucleophilic addition of various ylides. Solid-phase glycosylation of peptides and enzymatic reactions were successfully performed with SPOCC resin. Enzymatic proteolytic cleavage of a resin-bound decapeptide on treatment with the 27 kDa protease subtilisin BNP' demonstrated the accessibility of the interior of the SPOCC resin for enzymes.

A bifunctional dimethylsulfoxide substitute enhances the aqueous solubility of small organic molecules

An oxetane-substituted sulfoxide has demonstrated potential as a dimethylsulfoxide substitute for enhancing the dissolution of organic compounds with poor aqueous solubilities. This sulfoxide may find utility in applications of library storage and biological assays. For the model compounds studied, significant solubility enhancements were observed using the sulfoxide as a cosolvent in aqueous media. Brine shrimp, breast cancer (MDA-MB-231), and liver cell line (HepG2) toxicity data for the new additive are also presented, in addition to comparative IC50 values for a series of PKD1 inhibitors.

SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES

The present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives of formula (I), in which A, X, R1, R2a, R2b, R3a, R3b, R4a and R4b are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, repectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.

PYRIDINE DERIVATIVE AS ASK1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF

Disclosed in the present invention are a compound as shown in formula (II), a tautomer or a pharmaceutically acceptable salt thereof, and also disclosed is the use thereof in preparing a drug for treating an ASK1-associated disease.

OXYSTEROLS AND METHODS OF USE THEREOF

Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R5, R6, and RG are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

DIHYDROQUINOLIZINONES AS ANTIVIRALS

Compounds, specifically hepatitis B virus and/or hepatitis D virus inhibitors, more specifically compounds that inhibit HBe antigen and HBs antigen in a subject, for the treatment of viral infections, and methods of preparing and using such compounds. Formula (I):

COMPOUNDS FOR BONE HEALING

Disclosed herein are embodiments of a method of accelerating bone healing in a subject in need thereof, comprising administering to the subject a compound disclosed here. The method may further comprise selecting or identifying a subject that has bone damage, or is a risk of developing bone damage. The compound may be administered after bone damage has occurred, or it may be administered prophylactically. The compound may be administered to a subject that has not and/or will not be exposed to radiation. In other embodiments, the subject has been and/or will be exposed to radiation.

Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies

We report here the discovery and pharmacological characterization of N-(1-benzyl-1H-pyrazol-3-yl)-2-phenylacetamide derivatives as potent, selective, brain-penetrating T-type calcium channel blockers. Optimization focused mainly on solubility, brain penetration, and the search for an aminopyrazole metabolite that would be negative in an Ames test. This resulted in the preparation and complete characterization of compound 66b (ACT-709478), which has been selected as a clinical candidate.

ETHER COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.